Earnings ·
Reports Q3 net revenues of $290.8M, raises full-year adjusted non-GAAP EBITDA guidance to $290-$300M
ANIPAni Pharmaceuticals Inc
ANI Pharmaceuticals reported third-quarter 2026 total net revenues of $290.8 million, a 27.6% increase year-over-year, driven by strong performance in its Rare Disease and Generics segments. Cortrophin Gel net revenues rose 36.1% to $138.7 million, while ILUVIEN revenues increased 34.1% to $22.3 million. The company reported diluted GAAP earnings per share of $1.51 and adjusted non-GAAP diluted EPS of $2.70. Management narrowed full-year total revenue guidance to $1,085-$1,125 million but raised adjusted non-GAAP EBITDA guidance to $290-$300 million and adjusted non-GAAP diluted EPS to $9.37-$9.71. Additionally, ANI announced a recommended public offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million) to expand its rare disease portfolio with EMCITATE. The company also repurchased $20 million in common stock year-to-date under its authorized buyback program. ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics for rare diseases, generics, and branded products.